GlassScriptPhysician profile
Jeffrey Rothman
NPI 1811982812
$5,210.05
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $1,216 · 2021: $909 · 2022: $1,109 · 2023: $846 · 2024: $95.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,039.92 | 2019-2023 | Ozempic, Rybelsus, Sogroya |
| Amgen INC. | $664.88 | 2019-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $515.70 | 2019-2022 | |
| Abbvie INC. | $477.00 | 2019-2023 | Synthroid |
| Abbott Laboratories | $408.38 | 2019-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $331.10 | 2021-2023 | Unithroid |
| Radius Health, INC. | $320.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $248.64 | 2019-2023 | Steglatro |
| Lilly USA, LLC | $222.61 | 2019-2023 | Mounjaro, Retevmo, Lyumjev |
| Medtronic Minimed, INC. | $153.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $149.61 | 2019 | |
| Dexcom, INC. | $119.17 | 2021-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $104.32 | 2021-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $55.45 | 2019-2023 | |
| Celgene Corporation | $52.50 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $43.35 | 2023 | |
| Corcept Therapeutics | $38.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.05 | 2020-2023 | Jardiance |
| Cequr Corporation | $28.20 | 2022-2024 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $23.05 | 2022 | |
| Amryt Pharma Holdings LTD | $21.95 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.28 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $18.58 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.42 | 2022 | |
| Medtronic, INC. | $16.50 | 2021 | |
| Tolmar, INC. | $15.85 | 2023 | |
| Vistapharm, INC. | $15.26 | 2021 | |
| Ibsa Pharma INC. | $14.99 | 2019 | |
| Lifescan, INC. | $14.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.79 | 2021 | |
| Advanced Oxygen Therapy INC. | $13.62 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.